ADMA BIOLOGICS INC - COMMON STOCK

ADMA Biologics Reports Fourth Quarter and Full Year 2020 Financial Results

25 Mar 2021 16:05:01 By Nasdaq GlobeNewswire

ADMA Biologics to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021

18 Mar 2021 08:00:00 By Nasdaq GlobeNewswire

ADMA Biologics to Participate in the Jefferies Virtual Plasma Summit

04 Mar 2021 08:00:02 By Nasdaq GlobeNewswire

ADMA Biologics Expands Global Regulatory Approval Presence and Announces FDA Approval to Commence Hepatitis B Plasma Collections

03 Mar 2021 08:00:01 By Nasdaq GlobeNewswire

ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting

26 Feb 2021 08:00:00 By Nasdaq GlobeNewswire

ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Knoxville, TN

01 Feb 2021 08:00:01 By Nasdaq GlobeNewswire

ADMA Biologics Receives Unique Permanent J-Code for ASCENIV™

26 Jan 2021 08:00:02 By Nasdaq GlobeNewswire

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2020 Revenues and Provides 2021 Strategic Outlook

19 Jan 2021 08:00:01 By Nasdaq GlobeNewswire

ADMA Biologics Receives Unique Temporary C-Code and Pass-Through Payment Status for ASCENIV™

04 Jan 2021 08:00:01 By Nasdaq GlobeNewswire